| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Urinary-cell mRNA profile and acute cellular rejection in kidney allografts.
|
N Engl J Med
|
2013
|
7.40
|
|
2
|
The international position on laparoscopic liver surgery: The Louisville Statement, 2008.
|
Ann Surg
|
2009
|
5.33
|
|
3
|
Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes.
|
Gastroenterology
|
2009
|
3.57
|
|
4
|
Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis.
|
Hepatology
|
2008
|
3.52
|
|
5
|
Alpha-fetoprotein response after locoregional therapy for hepatocellular carcinoma: oncologic marker of radiologic response, progression, and survival.
|
J Clin Oncol
|
2009
|
3.43
|
|
6
|
Chimerism and tolerance without GVHD or engraftment syndrome in HLA-mismatched combined kidney and hematopoietic stem cell transplantation.
|
Sci Transl Med
|
2012
|
3.27
|
|
7
|
Evaluation of 300 minimally invasive liver resections at a single institution: less is more.
|
Ann Surg
|
2007
|
2.67
|
|
8
|
Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma.
|
Gastroenterology
|
2010
|
2.35
|
|
9
|
Unresectable solitary hepatocellular carcinoma not amenable to radiofrequency ablation: multicenter radiology-pathology correlation and survival of radiation segmentectomy.
|
Hepatology
|
2014
|
2.14
|
|
10
|
A comprehensive risk assessment of mortality following donation after cardiac death liver transplant - an analysis of the national registry.
|
J Hepatol
|
2011
|
1.94
|
|
11
|
Intrahepatic biliary cystadenoma: role of cyst fluid analysis and surgical management in the laparoscopic era.
|
Surgery
|
2004
|
1.89
|
|
12
|
Imaging response in the primary index lesion and clinical outcomes following transarterial locoregional therapy for hepatocellular carcinoma.
|
JAMA
|
2010
|
1.84
|
|
13
|
Laparoscopic liver surgery: Shifting the management of liver tumors.
|
Hepatology
|
2006
|
1.58
|
|
14
|
Safety, tolerability, and efficacy of everolimus in de novo liver transplant recipients: 12- and 36-month results.
|
Liver Transpl
|
2006
|
1.56
|
|
15
|
Systemic immunoregulatory and proteogenomic effects of tacrolimus to sirolimus conversion in liver transplant recipients.
|
Hepatology
|
2012
|
1.56
|
|
16
|
Validation of a current definition of early allograft dysfunction in liver transplant recipients and analysis of risk factors.
|
Liver Transpl
|
2010
|
1.56
|
|
17
|
Living kidney donor follow-up: state-of-the-art and future directions, conference summary and recommendations.
|
Am J Transplant
|
2011
|
1.51
|
|
18
|
Comparative effectiveness of liver transplant strategies for end-stage liver disease patients on renal replacement therapy.
|
Liver Transpl
|
2014
|
1.50
|
|
19
|
Tolerance induction in HLA disparate living donor kidney transplantation by donor stem cell infusion: durable chimerism predicts outcome.
|
Transplantation
|
2013
|
1.50
|
|
20
|
Living donor liver transplantation for hepatocellular carcinoma.
|
Gastroenterology
|
2004
|
1.45
|
|
21
|
Radiologic-pathologic correlation of hepatocellular carcinoma treated with internal radiation using yttrium-90 microspheres.
|
Hepatology
|
2009
|
1.44
|
|
22
|
Role of the EASL, RECIST, and WHO response guidelines alone or in combination for hepatocellular carcinoma: radiologic-pathologic correlation.
|
J Hepatol
|
2010
|
1.25
|
|
23
|
Radiographic response to locoregional therapy in hepatocellular carcinoma predicts patient survival times.
|
Gastroenterology
|
2011
|
1.25
|
|
24
|
Radiologic-pathologic correlation of hepatocellular carcinoma treated with chemoembolization.
|
Cardiovasc Intervent Radiol
|
2009
|
1.18
|
|
25
|
Dual-echo, chemical shift gradient-echo magnetic resonance imaging to quantify hepatic steatosis: Implications for living liver donation.
|
Liver Transpl
|
2003
|
1.12
|
|
26
|
Radiation lobectomy: time-dependent analysis of future liver remnant volume in unresectable liver cancer as a bridge to resection.
|
J Hepatol
|
2013
|
1.08
|
|
27
|
The economic impact of MELD on liver transplant centers.
|
Am J Transplant
|
2005
|
1.05
|
|
28
|
Quality of life for donors after living donor liver transplantation: a review of the literature.
|
Liver Transpl
|
2010
|
0.98
|
|
29
|
A randomized, multicenter study comparing steroid-free immunosuppression and standard immunosuppression for liver transplant recipients with chronic hepatitis C.
|
Liver Transpl
|
2011
|
0.97
|
|
30
|
Alpha-fetoprotein response correlates with EASL response and survival in solitary hepatocellular carcinoma treated with transarterial therapies: a subgroup analysis.
|
J Hepatol
|
2012
|
0.96
|
|
31
|
Laparoscopic liver resection.
|
J Am Coll Surg
|
2005
|
0.95
|
|
32
|
Radiological-pathological analysis of WHO, RECIST, EASL, mRECIST and DWI: Imaging analysis from a prospective randomized trial of Y90 ± sorafenib.
|
Hepatology
|
2013
|
0.95
|
|
33
|
Genomic biomarkers correlate with HLA-identical renal transplant tolerance.
|
J Am Soc Nephrol
|
2013
|
0.94
|
|
34
|
Establishment of murine cytomegalovirus latency in vivo is associated with changes in histone modifications and recruitment of transcriptional repressors to the major immediate-early promoter.
|
J Virol
|
2008
|
0.92
|
|
35
|
Mortality in candidates waiting for combined liver-intestine transplants exceeds that for other candidates waiting for liver transplants.
|
Liver Transpl
|
2003
|
0.91
|
|
36
|
Extrahepatic metastases occur in a minority of hepatocellular carcinoma patients treated with locoregional therapies: analyzing patterns of progression in 285 patients.
|
Hepatology
|
2012
|
0.91
|
|
37
|
Immunoregulatory profiles in liver transplant recipients on different immunosuppressive agents.
|
Hum Immunol
|
2009
|
0.91
|
|
38
|
Preoperative evaluation of the entire hepatic vasculature in living liver donors with use of contrast-enhanced MR angiography and true fast imaging with steady-state precession.
|
J Vasc Interv Radiol
|
2003
|
0.89
|
|
39
|
Should the liver transplant criteria for hepatocellular carcinoma be different for deceased donation and living donation?
|
Liver Transpl
|
2011
|
0.88
|
|
40
|
Donation after cardiac death liver transplantation: time for policy to catch up with practice.
|
Liver Transpl
|
2012
|
0.88
|
|
41
|
Renal ischemia/reperfusion injury activates the enhancer domain of the human cytomegalovirus major immediate early promoter.
|
Am J Transplant
|
2005
|
0.87
|
|
42
|
Biphasic recruitment of transcriptional repressors to the murine cytomegalovirus major immediate-early promoter during the course of infection in vivo.
|
J Virol
|
2010
|
0.87
|
|
43
|
Clinical Trials for Immunosuppression in Transplantation; The Case for Reform and Change in Direction.
|
Transplantation
|
2017
|
0.87
|
|
44
|
Radiation segmentectomy: a novel approach to increase safety and efficacy of radioembolization.
|
Int J Radiat Oncol Biol Phys
|
2010
|
0.86
|
|
45
|
Transcriptional reactivation of murine cytomegalovirus ie gene expression by 5-aza-2'-deoxycytidine and trichostatin A in latently infected cells despite lack of methylation of the major immediate-early promoter.
|
J Gen Virol
|
2007
|
0.85
|
|
46
|
Bile duct injuries 12 years after the introduction of laparoscopic cholecystectomy.
|
J Gastrointest Surg
|
2003
|
0.85
|
|
47
|
Epigenetic control of cytomegalovirus latency and reactivation.
|
Viruses
|
2013
|
0.85
|
|
48
|
Aasld guidelines for the treatment of hepatocellular carcinoma.
|
Hepatology
|
2017
|
0.83
|
|
49
|
Intragraft TNF receptor signaling contributes to activation of innate and adaptive immunity in a renal allograft model.
|
Transplantation
|
2009
|
0.83
|
|
50
|
Hemodynamic evaluation before liver transplantation: insights into the portal hypertensive syndrome.
|
J Clin Gastroenterol
|
2007
|
0.82
|
|
51
|
Impact of parenteral nutrition-associated liver disease on intestinal transplant waitlist dynamics.
|
J Am Coll Surg
|
2007
|
0.82
|
|
52
|
Defining long-term outcomes with living donor liver transplantation in North America.
|
Ann Surg
|
2015
|
0.82
|
|
53
|
Frequency and significance of acute heart failure following liver transplantation.
|
Am J Cardiol
|
2008
|
0.81
|
|
54
|
Transplant tourism and unregulated black-market trafficking of organs.
|
Am J Transplant
|
2009
|
0.80
|
|
55
|
Treating and downstaging hepatocellular carcinoma in the caudate lobe with yttrium-90 radioembolization.
|
Cardiovasc Intervent Radiol
|
2011
|
0.80
|
|
56
|
ACE gene D/D genotype as a risk factor for chronic nephrotoxicity from calcineurin inhibitors in liver transplant recipients.
|
Transplantation
|
2006
|
0.79
|
|
57
|
Simulation modeling of the impact of proposed new simultaneous liver and kidney transplantation policies.
|
Transplantation
|
2015
|
0.78
|
|
58
|
The renal benefit of mycophenolate mofetil after liver transplantation.
|
Clin Transplant
|
2010
|
0.78
|
|
59
|
TNF receptor independent activation of the cytomegalovirus major immediate early enhancer in response to transplantation.
|
Transplantation
|
2008
|
0.78
|
|
60
|
HLA identical non-chimeric and HLA disparate chimeric renal transplant tolerance.
|
Clin Transpl
|
2013
|
0.78
|
|
61
|
Alemtuzumab induction in non-hepatitis C positive liver transplant recipients.
|
Liver Transpl
|
2011
|
0.77
|
|
62
|
TNF-alpha signaling is not required for in vivo transcriptional reactivation of latent murine cytomegalovirus.
|
Transplantation
|
2009
|
0.77
|
|
63
|
Making dollars and sense out of liver transplantation.
|
Liver Transpl
|
2009
|
0.76
|
|
64
|
Mycophenolate mofetil monotherapy in liver transplant recipients.
|
Clin Transplant
|
2011
|
0.76
|
|
65
|
Pretransplant Portal Vein Recanalization-Transjugular Intrahepatic Portosystemic Shunt in Patients With Complete Obliterative Portal Vein Thrombosis.
|
Transplantation
|
2015
|
0.76
|
|
66
|
To kidney or not to kidney, when … is the question.
|
Liver Transpl
|
2012
|
0.75
|
|
67
|
Is antifibrinolytic drug use in liver transplantation associated with an increased risk of thromboembolic events?
|
Nat Clin Pract Gastroenterol Hepatol
|
2007
|
0.75
|
|
68
|
Living donor liver transplant for malignancy.
|
Transplantation
|
2005
|
0.75
|
|
69
|
Split liver sharing in the United States.
|
Am J Transplant
|
2005
|
0.75
|
|
70
|
Biomarker Guidelines for High-Dimensional Genomic Studies in Transplantation: Adding Method to the Madness.
|
Transplantation
|
2017
|
0.75
|